641569-97-3

4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid ethyl ester is a pharmaceutical intermediate compound used in the preparation of nilotinib, a transactivation inhibitor targeting BCR-ABL, c-kit, and PDGF, which is used in the treatment of a variety of leukaemia, including chronic granulocytic leukaemia (CML). Chronic granulocytic leukaemia (CML) is caused by the BCR-ABL oncogene. Nilotinib inhibits the tyrosine kinase activity of the BCR-ABL protein.